A GOP congressman who is spearheading a medical cannabis reform law has questioned this week’s decision to allow Canada-based Tilray Inc. to import the drug for use in a clinical trial

A GOP congressman who is spearheading a medical cannabis reform law has questioned this week’s decision to allow Canada-based Tilray Inc. to import the drug for use in a clinical trial https://t.co/A1spvmEa0J

— MarketWatch (@MarketWatch) September 22, 2018